Skip to Content

Anidulafungin Dosage

Medically reviewed by Drugs.com. Last updated on Feb 26, 2020.

Applies to the following strengths: 50 mg; 100 mg

Usual Adult Dose for Esophageal Candidiasis

Initial dose: 100 mg IV on Day 1
Maintenance dose: 50 mg IV once a day thereafter

Duration of therapy: At least 14 days and at least 7 days after resolution of symptoms

Comments:
-Treatment duration should be based on the patient's clinical response.
-Due to risk of relapse in HIV-infected patients, suppressive antifungal therapy may be considered after a course of treatment.

Use: For the treatment of esophageal candidiasis

Usual Adult Dose for Candidemia

Initial dose: 200 mg IV on Day 1
Maintenance dose: 100 mg IV once a day thereafter

Comments:
-Treatment duration should be based on the patient's clinical response; in general, antifungal therapy should continue for at least 14 days after the last positive culture.

Use: For the treatment of candidemia and the following Candida infections: intraabdominal abscess and peritonitis

Usual Pediatric Dose for Esophageal Candidiasis

Greater than 16 years:
-Initial dose: 100 mg IV on Day 1
-Maintenance dose: 50 mg IV once a day thereafter

Duration of therapy: At least 14 days and at least 7 days after resolution of symptoms

Comments:
-Treatment duration should be based on the patient's clinical response.
-Due to risk of relapse in HIV-infected patients, suppressive antifungal therapy may be considered after a course of treatment.

Use: For the treatment of esophageal candidiasis

Usual Pediatric Dose for Candidemia

Greater than 16 years:
-Initial dose: 200 mg IV on Day 1
-Maintenance dose: 100 mg IV once a day thereafter

Comments:
-Treatment duration should be based on the patient's clinical response; in general, antifungal therapy should continue for at least 14 days after the last positive culture.

Use: For the treatment of candidemia and the following Candida infections: intraabdominal abscess and peritonitis

Renal Dose Adjustments

Any degree of renal dysfunction: No adjustment recommended.

Liver Dose Adjustments

Any degree of liver dysfunction: No adjustment recommended.

Precautions

CONTRAINDICATIONS:
Known hypersensitivity to the active component, any of the ingredients, or other echinocandins

Safety and efficacy have not been established in patients 16 years or younger.

Consult WARNINGS section for additional precautions.

Dialysis

Hemodialysis: No adjustment recommended.

Comments:
-This drug is not dialyzable and may be administered without regard to the timing of hemodialysis.

Other Comments

Administration advice:
-For IV use
-Do not exceed a rate of infusion of 1.1 mg/minute.

Storage requirements:
-Unreconstituted vials: Store in refrigerator at 2C to 8C (36F to 46F); do not freeze. Excursions for 96 hours up to 25C (77F) permitted and vial can be returned to storage at 2C to 8C (36F to 46F).
-Reconstituted solution: Can store at up to 25C (77F) for up to 24 hours before dilution into infusion solution; chemical and physical in-use stability shown for 24 hours at 25C (77F).
-Diluted infusion solution: Can store at up to 25C (77F) for up to 48 hours or frozen for at least 72 hours; chemical and physical in-use stability shown for 48 hours at 25C (77F) or 72 hours when stored frozen.

Reconstitution/preparation techniques:
-The manufacturer's product information should be consulted.

IV compatibility:
-Compatible (reconstitution): Sterile Water for Injection
-Compatible (dilution): 5% Dextrose Injection, USP; 0.9% Sodium Chloride Injection, USP
-Compatibility of the reconstituted solution with other IV substances, additives, or medications has not been established.

General:
-Limitations of use: This drug has not been studied in endocarditis, osteomyelitis, and meningitis due to Candida and has not been studied in enough neutropenic patients to establish efficacy in this group.
-Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be collected before therapy to isolate and identify causative organism(s); therapy may be started before results of cultures and other laboratory studies are known; antifungal therapy should be adjusted accordingly when results are available.

Monitoring:
-Hepatic: For evidence of worsening hepatic function in patients who develop abnormal liver function tests (during therapy)

Patient advice:
-Notify healthcare provider if infusion-related symptoms (including rash, urticaria, flushing, pruritus, dyspnea, hypotension) occur.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide